Finally, a synthetic GC was shown to up-regulate peripheral CNR1 expression, suggesting it is involved in GR-regulated lipolysis making it an attractive drug target in type 2 diabetes and dyslipidemia [149]. This evidence concerns the gene NR3C1 and metabolic syndrome.